OPDUALAG DIN 02541416
Status: Marketed
Holder: BRISTOL-MYERS SQUIBB CANADA
Available to quote
Health Canada record
| Active ingredient(s) | NIVOLUMAB 240 MG; RELATLIMAB 80 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Intravenous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01FY02 NIVOLUMAB AND RELATLIMAB |
|---|
| Original market date | 12-Feb-2024 |
|---|
| Current status date | 12-Feb-2024 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Bristol-Myers Squibb Canada — licence 100100, currently licensed, last inspection rating C (2026-03-18).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing NIVOLUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02446626 | OPDIVO | BRISTOL-MYERS SQUIBB CANADA | Solution | NIVOLUMAB 10 MG | Marketed |
| 02446634 | OPDIVO | BRISTOL-MYERS SQUIBB CANADA | Solution | NIVOLUMAB 10 MG | Marketed |
| 02557320 | OPDIVO SC | BRISTOL-MYERS SQUIBB CANADA | Solution | NIVOLUMAB 120 MG | Marketed |
| 02566931 | OPDIVO SC | BRISTOL-MYERS SQUIBB CANADA | Solution | NIVOLUMAB 120 MG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 31617 | 2023-09-13 | New Drug Submission (NDS) | |
Request a quote for OPDUALAG
How to read a Canadian DIN record